19Dec
Understanding H3N2 and the Emerging Subclade K: Strengthening Respiratory Surveillance with Seegene’s Comprehensive Panels
Respiratory viruses continue to evolve rapidly, posing ongoing challenges for clinical laboratories and public health systems. Among seasonal influenza strains, Influenza A subtype H3N2 has long been a significant contributor to global respiratory disease burden. In the current 2025–26 Northern Hemisphere season, a particular lineage known as H3N2 subclade K (also referred to in nomenclature as J.2.4.1) has risen sharply in prevalence worldwide, underscoring the critical importance of robust respiratory surveillance to detect and monitor emerging variants.
What Is H3N2 and Subclade K?
Influenza A(H3N2) is a subtype of influenza virus that circulates widely in humans, especially during seasonal outbreaks. It is characterised by the “H3” haemagglutinin and “N2” neuraminidase surface proteins, which evolve over time through antigenic drift. Genetic surveillance efforts during 2025 have documented a rapid global increase of the H3N2 subclade K lineage — a phylogenetically distinct subgroup within broader H3N2 circulation. Subclade K has been detected across multiple continents and is a major driver of influenza activity in regions including Europe, North America, and parts of Asia.
Public health organisations, including the Pan American Health Organization (PAHO) and World Health Organization (WHO), have emphasised intensified respiratory surveillance and vaccination efforts in response to the rise of subclade K. Although no significant changes in disease severity have been reported compared with other H3N2 seasons, historical patterns indicate that H3N2-dominant seasons often impose a higher disease burden, particularly among older adults and individuals with underlying health conditions.
The Role of Respiratory Surveillance
Effective respiratory surveillance involves timely detection and characterisation of circulating pathogens to guide clinical management, inform infection control, and support public health decision-making. With influenza viruses and other respiratory pathogens co-circulating — including RSV, coronaviruses, parainfluenza viruses, and atypical bacteria — multiplex molecular testing has become a cornerstone in comprehensive surveillance strategies.
Seegene’s Complete Respiratory Panels: Broad Pathogen Detection
As the official distributor of Seegene diagnostic solutions in Pakistan, AgileMeds is proud to offer Seegene’s industry-leading respiratory pathogen panels. Seegene’s Allplex™ and Novaplex™ respiratory assays provide high-throughput, multiplex real-time PCR detection of the most clinically relevant respiratory viruses and bacteria.
Seegene Respiratory Panel 1A
This panel enables essential screening for influenza A (including subtyping for H1, H1pdm09, and H3), influenza B, and Respiratory Syncytial Virus (RSV) A and B, all in a single assay. The inclusion of influenza A subtyping — especially H3 subtypes — enhances surveillance capacity for variants such as H3N2 and subclade K.
Seegene Respiratory Panel 2
Panel 2 detects a broader range of respiratory viruses, including adenovirus, enterovirus, human metapneumovirus, and all four parainfluenza virus types, supporting detailed differential diagnosis.
Seegene Respiratory Panel 3
Panel 3 targets additional viral pathogens frequently circulating during respiratory seasons, including bocavirus, rhinovirus, and common human coronaviruses (NL63, 229E, OC43). This expands viral detection beyond influenza and RSV.
Seegene Respiratory Panel 4
Crucially, Panel 4 covers key bacterial pathogens associated with respiratory infections, such as Bordetella pertussis, Bordetella parapertussis, Chlamydophila pneumoniae, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Streptococcus pneumoniae. This comprehensive inclusion supports detection of both viral and bacterial etiologies, enabling clinicians to pinpoint co-infections and adjust treatment strategies accordingly.
Together, these panels enable detection of up to 26 respiratory targets — including 16 viruses, three influenza A subtypes, and seven bacterial agents — from a single sample workflow. The multiplex design, compatible with automated extraction and PCR platforms, maximises throughput while reducing turnaround time and laboratory burden.
Why AgileMeds Offers Seegene for Pakistan
As global respiratory pathogens continue to evolve — illustrated by the ascent of H3N2 subclade K — robust molecular detection tools are essential for effective clinical and public health responses. AgileMeds, as the authorised distributor for Seegene in Pakistan, offers healthcare providers access to advanced respiratory surveillance platforms that support accurate, comprehensive pathogen detection.
These panels not only aid in routine diagnostic workflows but also contribute to sentinel surveillance programmes that track trends in circulating respiratory viruses and bacteria. Whether you are addressing peak influenza activity or investigating unexplained respiratory syndromes, Seegene’s complete respiratory panels equip your laboratory with reliable, high-fidelity data to guide decisions.